Assertio Holdings, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Brendan P. O'Grady
- Full Time Employees
- 53
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 100 South Saunders Road Lake Forest IL United States of America 60045
- IPO Date
- Dec 3, 1997
- CIK
- 0001808665
- Website
- assertiotx.com
- Similar Companies
- Business
- Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Company News
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Assertio Holdings: Management Change Could Improve Comeback Chances
Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024
Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
Assertio Reports Second Quarter 2024 Financial Results
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Assertio: An Extremely Asymmetric Bet Skewed To The Upside
3 Penny Stocks With 458% Average Upside According to Wall Street Analysts
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024
Assertio to Participate in Benchmark Healthcare Conference on May 21-22
BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS
Assertio to Participate in AGP Healthcare Conference on May 21
BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS
Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript